Brief: Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic
17/03/2026 11:51
March 17 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC HCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECH HCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTS Source text: ID:nGNXcc37Tx Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM